Successful financing round for FEops
FEops, a leader in personalized computer modeling for structural heart interventions, has secured a 6 million euros investment, led by Valiance, and joined by existing investors Capricorn and PMV. The funding will be used to aggressively implement the company’s product roadmap, centered around FEops HEARTguide, and drive commercial adoption in the fastgrowing market for transcatheter valve therapies.
FEops was founded in 2009 as a Ghent University spin-off. The company has developed a proprietary system to improve transcatheter valve procedures based on personalized computer simulations. Its first product, TAVIguide is currently the only CE-marked technology on the market that predicts how a TAVI implant will interact with the patient-specific aortic anatomy and thus provide clinically meaningful insights in the personalized device size selection and position. FEops’ pipeline extends to dedicated planning tools with unique potential in driving forward the development, testing and market adoption of new and improved device-based solutions in the structural heart space.
FEops HEARTguide proprietary array of products use advanced computer simulations to provide clinicians and valve manufacturers first-ever insights into the interaction between valve and specific patient anatomy – preoperatively. Such insights have tremendous power to accelerate research and development of novel valve-based solutions, as well as ultimately improve clinical outcomes in real-world hospital settings.